Base de dados : MEDLINE
Pesquisa : E02.319.698 [Categoria DeCS]
Referências encontradas : 3556 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 356 ir para página                         

  1 / 3556 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28743244
[Au] Autor:Bazargan M; Smith J; Yazdanshenas H; Movassaghi M; Martins D; Orum G
[Ad] Endereço:Charles R. Drew University of Medicine & Science, 1731 East 120th Street, Los Angeles, CA, 90005, USA. mobazarg@cdrewu.edu.
[Ti] Título:Non-adherence to medication regimens among older African-American adults.
[So] Source:BMC Geriatr;17(1):163, 2017 Jul 25.
[Is] ISSN:1471-2318
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Despite concerns about racial differences on adherence to prescribed medication rigimens among older adults, current information about nonadherence among underserved elderly African Americans with co-morbidities is limited. This study examines the association between adherence to drug regimens and an array of medication-related factors, including polypharmacy, medication regimen complexity, use of Potentially Inappropriate Medications (PIM), and knowledge about the therapeutic purpose and instructions of medication use. METHODS: Four-hundred African Americans, aged 65 years and older, were recruited from South Los Angeles. Structured, face-to-face interviews and visual inspection of participants' medications were conducted. From the medication container labels, information including strength of the drug, expiration date, instructions, and special warnings were recorded. The Medication Regimen Complexity Index (MRCI) was measured to quantify multiple features of drug regimen complexity. The Beers Criteria was used to measure the PIM use. RESULTS: Participants reported taking an average of 5.7 prescription drugs. Over 56% could not identify the purpose of at least one of their medications. Only two-thirds knew dosage regimen of their medications. Thirty-five percent of participants indicated that they purposely had skipped taking at least one of their medications within last three days. Only 8% of participants admitted that they forgot to take their medications. The results of multivariate analysis showed that co-payment for drugs, memory deficits, MRCI, and medication-related knowledge were all associated with adherence to dosage regimen of medications. Participants with a higher level of knowledge about therapeutic purpose and knowledge about dosage regimen of their medications were seven times (CI: 4.2-10.8) more likely to adhere to frequency and dose of medications. Participants with a low complexity index were two times (CI: 1.1-3.9) more likely to adhere to the dosage regimen of their medications, compared with participants with high drug regimen complexity index. CONCLUSIONS: While other studies have documented that non-adherence remains an important issue among older adults, our study shows that for underserved elderly African Americans, these issues are particularly striking. A periodic comprehensive assessment of all medications that they use remains a critical initial step to identify medication related issues. Assessment of their disease and medication related knowledge (e.g., therapeutic purposes, side-effects, special instructions, etc.) and their ability to follow complicated medication regimens and modification of their drug regimens requires inter-professional collaboration.
[Mh] Termos MeSH primário: Afroamericanos/psicologia
Conhecimentos, Atitudes e Prática em Saúde
Alfabetização em Saúde/métodos
Adesão à Medicação/psicologia
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Estudos Transversais
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/diagnóstico
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/epidemiologia
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/prevenção & controle
Feminino
Hospitalização/tendências
Seres Humanos
Masculino
Educação de Pacientes como Assunto/métodos
Polimedicação
Lista de Medicamentos Potencialmente Inapropriados/tendências
Medicamentos sob Prescrição/efeitos adversos
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Prescription Drugs)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170727
[St] Status:MEDLINE
[do] DOI:10.1186/s12877-017-0558-5


  2 / 3556 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29369280
[Au] Autor:Smith DMR; Kautz DD
[Ad] Endereço:Debbie Montgomery R. Smith is an emergency nurse at W. G. (Bill) Hefner VA Medical Center in Salisbury, N.C., and float pool nurse at Wake Forest Baptist Health-Lexington Medical Center in Lexington, N.C. Donald Kautz is retired, Associate Professor Emeritus, in the School of Nursing at the University of North Carolina Greensboro.
[Ti] Título:Protect older adults from polypharmacy hazards.
[So] Source:Nursing;48(2):56-59, 2018 Feb.
[Is] ISSN:1538-8689
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Tratamento Farmacológico/enfermagem
Enfermagem Geriátrica
Polimedicação
[Mh] Termos MeSH secundário: Idoso
Comorbidade
Seres Humanos
Adesão à Medicação
Relações Enfermeiro-Paciente
Avaliação em Enfermagem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:180126
[St] Status:MEDLINE
[do] DOI:10.1097/01.NURSE.0000527602.17216.6d


  3 / 3556 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29233271
[Au] Autor:Howell CK; Reveles KR; Knodel LC; Pattyn NR; Frei CR
[Ad] Endereço:College of Pharmacy, The University of Texas at Austin, Austin, TX; Pharmacotherapy Education and Research Center, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX. Electronic address: crystal.howell@emoryhealthcare.org.
[Ti] Título:Know your medicine: A novel student-led community service learning program.
[So] Source:Curr Pharm Teach Learn;9(3):353-359, 2017 May.
[Is] ISSN:1877-1300
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: The objective of this article is to describe the efforts of the student pharmacist organization called Know Your Medicine (KYM) as they conduct medication therapy management (MTM) for older adults and underserved communities. METHODS: Patients brought medications, immunization records, and health concerns to KYM events during academic years 2012-2013 and 2013-2014. Student pharmacists performed health screenings, created personalized medication records (PMR), made recommendations, created personal action plans (PAP), and conducted follow-up phone calls. RESULTS: Student pharmacists provided MTM services for a total of 107 patients. The mean duration of a KYM appointment was 62±21min, and student pharmacists provided a mean of 3.5±2.1 recommendations per patient. Patients had a mean age of 78±11 years, 4.5±3.2 disease states, 6.9±4.6 prescriptions, 1.9±1.9 OTC medications, and 2.8±2.6 vitamins or herbals. At the time of the follow-up phone call, a mean of 2.6±1.9 recommendations per patient had been followed. DISCUSSION AND CONCLUSIONS: Student pharmacists successfully implemented a new MTM program for older adults and underserved communities. This program can serve as an example of how other pharmacy colleges and schools might implement MTM training and real-world MTM experience for their student pharmacists.
[Mh] Termos MeSH primário: Conduta do Tratamento Medicamentoso/organização & administração
Conduta do Tratamento Medicamentoso/estatística & dados numéricos
Estudantes de Farmácia
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Relações Comunidade-Instituição
Comorbidade
Prescrições de Medicamentos/estatística & dados numéricos
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/prevenção & controle
Educação em Farmácia
Feminino
Seres Humanos
Masculino
Aceitação pelo Paciente de Cuidados de Saúde
Polimedicação
Seguridade Social
Telefone
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171214
[St] Status:MEDLINE


  4 / 3556 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29297215
[Au] Autor:Rosso AM
[Ti] Título:Alexandria, An emporium in the Silk Road, and the Traffic of Unusual Medicines.
[So] Source:Vesalius;22(2 Suppl):26-52, 2016 Dec.
[Is] ISSN:1373-4857
[Cp] País de publicação:Belgium
[La] Idioma:eng
[Ab] Resumo:In Ancient times, an active trade of exotic and peculiar drugs tool place along the Silk Road. Coming through China, India, Central Asia, Armenia, including Colchis, Arabia, Nubia as far as Greece and Rome, it was centered during Ptolemaic and Roman times in Alexandria, the world Emporium, remarkably advanced in scientific medicine. Physicians required a variety of active ingredients for their pharmacotherapy, following various related branches of medicine. These included: 1) herbal remedies: including toxic plants 2) polypharmacy: missing together all kind of drugs 3) dreckapotheke or copropharmacy, employing unclean materials 4) organic therapy, using exotic or domestic animal products 5) aromatherapy, lined to essential oils and perfumes 6) 'medical astrology and botany', regarding the laws of sympathy in the natural world 7) alchemy and magic medicine: with occult knowledge
[Mh] Termos MeSH primário: Comércio/história
Mundo Grego/história
Medicina Tradicional/história
Farmácia/história
Mundo Romano/história
Seda/história
[Mh] Termos MeSH secundário: Cidades
Egito
Medicina Herbária/história
História Antiga
Polimedicação
Seda/economia
[Pt] Tipo de publicação:HISTORICAL ARTICLE; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Silk)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180212
[Lr] Data última revisão:
180212
[Sb] Subgrupo de revista:QIS
[Da] Data de entrada para processamento:180104
[St] Status:MEDLINE


  5 / 3556 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29241884
[Au] Autor:Brekke L; Buysman E; Grabner M; Ke X; Xie L; Baser O; Wei W
[Ad] Endereço:Optum, Eden Prairie, MN, USA. Electronic address: lee.brekke@optum.com.
[Ti] Título:The Use of Decomposition Methods in Real-World Treatment Benefits Evaluation for Patients with Type 2 Diabetes Initiating Different Injectable Therapies: Findings from the INITIATOR Study.
[So] Source:Value Health;20(10):1252-1259, 2017 12.
[Is] ISSN:1524-4733
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Determining characteristics of patients likely to benefit from a particular treatment could help physicians set personalized targets. OBJECTIVES: To use decomposition methodology on real-world data to identify the relative contributions of treatment effects and patients' baseline characteristics. METHODS: Decomposition analyses were performed on data from the Initiation of New Injectable Treatment Introduced after Antidiabetic Therapy with Oral-only Regimens (INITIATOR) study, a real-world study of patients with type 2 diabetes started on insulin glargine (GLA) or liraglutide (LIRA). These analyses investigated relative contributions of differences in baseline characteristics and treatment effects to observed differences in 1-year outcomes for reduction in glycated hemoglobin A (HbA ) and treatment persistence. RESULTS: The greater HbA reduction seen with GLA compared with LIRA (-1.39% vs. -0.74%) was primarily due to differences in baseline characteristics (HbA and endocrinologist as prescribing physician; P < 0.050). Patients with baseline HbA of 9.0% or more or evidence of diagnosis codes related to mental illness achieved greater HbA reductions with GLA, whereas patients with baseline polypharmacy (6-10 classes) or hypogylcemia achieved greater reductions with LIRA. Decomposition analyses also showed that the higher persistence seen with GLA (65% vs. 49%) was mainly caused by differences in treatment effects (P < 0.001). Patients 65 years and older, those with HbA of 9.0% or more, those taking three oral antidiabetes drugs, and those with polypharmacy of more than 10 classes had higher persistence with GLA; patients 18 to 39 years and those with HbA of 7.0% to less than 8.0% had higher persistence with LIRA. CONCLUSIONS: Although decomposition does not demonstrate causal relationships, this method could be useful for examining the source of differences in outcomes between treatments in a real-world setting and could help physicians identify patients likely to respond to a particular treatment.
[Mh] Termos MeSH primário: Diabetes Mellitus Tipo 2/tratamento farmacológico
Hemoglobina A Glicada/metabolismo
Hipoglicemiantes/administração & dosagem
Insulina Glargina/administração & dosagem
Liraglutida/administração & dosagem
[Mh] Termos MeSH secundário: Adolescente
Adulto
Fatores Etários
Idoso
Feminino
Seres Humanos
Injeções
Masculino
Adesão à Medicação/estatística & dados numéricos
Meia-Idade
Polimedicação
Análise de Regressão
Estudos Retrospectivos
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Glycated Hemoglobin A); 0 (Hypoglycemic Agents); 2ZM8CX04RZ (Insulin Glargine); 839I73S42A (Liraglutide)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180202
[Lr] Data última revisão:
180202
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171216
[St] Status:MEDLINE


  6 / 3556 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29210867
[Au] Autor:Aly El-Gabry DM; Abdel Aziz K; Okasha T; Azzam H; Okasha A
[Ti] Título:Antipsychotic Polypharmacy and Its Relation to Metabolic Syndrome in Patients With Schizophrenia: An Egyptian Study.
[So] Source:J Clin Psychopharmacol;38(1):27-33, 2018 Feb.
[Is] ISSN:1533-712X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE/BACKGROUND: Few studies have examined the relationship between antipsychotic polypharmacy and metabolic syndrome in schizophrenia. Some studies suggest that antipsychotic polypharmacy may be associated with greater metabolic risk, whereas other studies suggest that this is uncertain. To date, there have been no studies in Egypt or the Arab world that have investigated this relationship. We sought to compare subjects with schizophrenia receiving antipsychotic polypharmacy and monotherapy as regards metabolic outcomes and to investigate medication-related factors associated with metabolic syndrome. METHODS/PROCEDURES: We recruited 118 subjects with schizophrenia and compared between those receiving antipsychotic polypharmacy (86 subjects) and monotherapy (32 subjects) as regards demographic, clinical, metabolic, and antipsychotic medication characteristics. We examined the effect of antipsychotic-related factors an outcome of metabolic syndrome. FINDINGS/RESULTS: The prevalence of metabolic syndrome in our sample was 38.1%. Except for gender, there was no statistically significant difference as regards demographic and clinical characteristics, rates of metabolic syndrome, or for individual metabolic parameters. We found a statistically significant difference (P < 0.05) between the 2 groups as regards the number, dose, and duration of intake and for the number of subjects receiving typical antipsychotics (oral and depot) and a number of individual antipsychotic medications. Using logistic regression, receiving haloperidol depot was the only antipsychotic-related factor predictive for metabolic syndrome. IMPLICATIONS/CONCLUSIONS: The prevalence of metabolic syndrome does not differ in schizophrenia whether patients are receiving polypharmacy and monotherapy nor do they differ for individual metabolic parameters. Most antipsychotic-related characteristics did not predict for metabolic syndrome.
[Mh] Termos MeSH primário: Antipsicóticos/administração & dosagem
Síndrome Metabólica/epidemiologia
Polimedicação
Esquizofrenia/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Antipsicóticos/efeitos adversos
Estudos Transversais
Preparações de Ação Retardada
Quimioterapia Combinada
Egito
Feminino
Haloperidol/administração & dosagem
Haloperidol/efeitos adversos
Seres Humanos
Modelos Logísticos
Masculino
Síndrome Metabólica/etiologia
Meia-Idade
Prevalência
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antipsychotic Agents); 0 (Delayed-Action Preparations); J6292F8L3D (Haloperidol)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180201
[Lr] Data última revisão:
180201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171207
[St] Status:MEDLINE
[do] DOI:10.1097/JCP.0000000000000815


  7 / 3556 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28457021
[Au] Autor:Nielsen TRH; Honoré PH; Rasmussen M; Andersen SE
[Ad] Endereço:Region Zealand Hospital Pharmacy, Logistics and Clinical Pharmacy, Roskilde, Denmark.
[Ti] Título:Clinical Effects of a Pharmacist Intervention in Acute Wards - A Randomized Controlled Trial.
[So] Source:Basic Clin Pharmacol Toxicol;121(4):325-333, 2017 Oct.
[Is] ISSN:1742-7843
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The purpose of the study was to investigate the clinical effect of a clinical pharmacist (CP) intervention upon admission to hospital on inpatient harm and to assess a potential educational bias. Over 16 months, 593 adult patients taking ≥4 medications daily were included from three Danish acute medicine wards. Patients were randomized to either the CP intervention or the usual care (prospective control). To assess a potential educational bias, a retrospective control group was formed by randomization. The CP intervention comprised medication history, medication reconciliation, medication review and entry of proposed prescriptions into the electronic prescribing system. The primary outcome of inpatient harm was identified using triggers from the Institute of Healthcare Improvement Global Trigger Tool. Harms were validated and rated for severity by two independent and blinded outcome panels. Secondary end-points were harms per patient, length of hospital stay, readmissions and 1-year mortality. Harm affected 11% of the patients in the intervention group compared to 17% in the combined control group, odds ratio (OR) 0.57 (CI 0.32-1.02, p = 0.06). The incidence of harm was similar in the intervention and prospective control groups, OR 0.80 (CI 0.40-1.59, p = 0.52) but occurred less frequently in the intervention than in the retrospective control group OR 0.46 (CI 0.25-0.85, p = 0.01). An educational bias from the intervention to the control group might have contributed to this negative outcome. In conclusion, the CP intervention at admission to hospital had no statistically significant effect on inpatient harm.
[Mh] Termos MeSH primário: Prescrição Eletrônica
Pacientes Internados
Reconciliação de Medicamentos
Sistemas de Medicação no Hospital
Conduta do Tratamento Medicamentoso
Farmacêuticos
Serviço de Farmácia Hospitalar
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Dinamarca
Interações Medicamentosas
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/etiologia
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/prevenção & controle
Feminino
Seres Humanos
Tempo de Internação
Masculino
Erros de Medicação/prevenção & controle
Meia-Idade
Admissão do Paciente
Segurança do Paciente
Polimedicação
Estudos Prospectivos
Estudos Retrospectivos
Fatores de Risco
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180130
[Lr] Data última revisão:
180130
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170501
[St] Status:MEDLINE
[do] DOI:10.1111/bcpt.12802


  8 / 3556 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29267348
[Au] Autor:Abe J; Umetsu R; Uranishi H; Suzuki H; Nishibata Y; Kato Y; Ueda N; Sasaoka S; Hatahira H; Motooka Y; Masuta M; Nakamura M
[Ad] Endereço:Laboratory of Drug Informatics, Gifu Pharmaceutical University, Daigaku-nishi, Gifu, Japan.
[Ti] Título:Analysis of polypharmacy effects in older patients using Japanese Adverse Drug Event Report database.
[So] Source:PLoS One;12(12):e0190102, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Population aging is a global phenomenon, and choosing appropriate medical care for the elderly is critical. Polypharmacy is suspected to increase the risk of adverse events (AEs) in older patients. We examined the AE profiles associated with polypharmacy and aging using the Japanese Adverse Drug Event Report (JADER) database. We attempted to mitigate the effect of patient-related factors using a multiple-logistic regression technique and data subsetting. We selected case reports for AEs as specified in the Medical Dictionary for Regulatory Activities (MedDRA). The association between polypharmacy and "renal disorder" or "hepatic disorder" was evaluated using reporting odds ratio (ROR) and adjusted for covariates using multiple-logistic regression. For renal disorder, advanced polypharmacy showed higher adjusted RORs, because the value of administered drugs group [1.82 (1.76-1.88), ≥ 10] was higher than that of the number of administered drugs group [1.27 (1.24-1.31), 5-9]. The lower limit of the 95% confidence interval (CI) of adjusted ROR for age (≥ 60 years) was > 1 for renal disorder. For hepatic disorder, the adjusted RORs were as follows: 1.17 (1.14-1.20) for the number of administered drugs group (5-9) and 1.14 (1.11-1.18) for the number of administered drugs group (≥ 10). The adjusted RORs of hepatic disorder compared to those of renal disorder had lower adjusted RORs related to the increase in the number of administered drugs. Therefore, elderly individuals should be closely monitored for the occurrence of renal disorder when they are subjected to polypharmacy. This approach might apply to the simultaneous evaluation of the AE risk of polypharmacy and aging.
[Mh] Termos MeSH primário: Sistemas de Notificação de Reações Adversas a Medicamentos
Polimedicação
[Mh] Termos MeSH secundário: Idoso
Feminino
Seres Humanos
Japão
Masculino
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180116
[Lr] Data última revisão:
180116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171222
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0190102


  9 / 3556 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28461603
[Au] Autor:Hyman DJ
[Ad] Endereço:From the Section of General Internal Medicine, Baylor College of Medicine, Houston, TX. dhyman@bcm.edu.
[Ti] Título:Hypertension: Does Polypharmacy Lead to Nonadherence or Nonadherence to Polypharmacy?
[So] Source:Hypertension;69(6):1017-1018, 2017 06.
[Is] ISSN:1524-4563
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Hipertensão
Polimedicação
[Mh] Termos MeSH secundário: Seres Humanos
Adesão à Medicação
[Pt] Tipo de publicação:EDITORIAL; COMMENT
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180116
[Lr] Data última revisão:
180116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE
[do] DOI:10.1161/HYPERTENSIONAHA.117.09334


  10 / 3556 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:29188972
[Au] Autor:Malm H; Ellfolk M
[Ti] Título:Which drugs can be used during pregnancy?
[So] Source:Duodecim;132(19):1781-9, 2016.
[Is] ISSN:0012-7183
[Cp] País de publicação:Finland
[La] Idioma:eng
[Ab] Resumo:In many cases the decisions on drug therapy during pregnancy have to be made without evidence-based information about the effectiveness and safety of the treatment. While few drugs are known with certainty to be harmful for fetal development, the evidence for evaluating harm to the fetus is insufficient for the majority of drugs. The differentiation of fetal organs takes place during the early weeks of pregnancy, whereby it is imperative that the mother's medication be revised already when planning a pregnancy. A drug should primarily be chosen, for which experience has accumulated about its use during pregnancy and is not suspected or known to be associated with adverse effects.
[Mh] Termos MeSH primário: Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos
Troca Materno-Fetal
Preparações Farmacêuticas/administração & dosagem
[Mh] Termos MeSH secundário: Anormalidades Induzidas por Medicamentos/etiologia
Feminino
Seres Humanos
Polimedicação
Gravidez
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Pharmaceutical Preparations)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171201
[St] Status:MEDLINE



página 1 de 356 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde